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Introduction
Inflammation is a pathophysiological
response to infection or tissue damage.
In order to neutralize the causing
agent, the innate immune system
launches a program that unfolds in
several phases (Soehnlein & Lindbom,
2010). Initially, tissue-resident cells of the innate immune
system detect the damaging insult and alarm circulating
neutrophils. These migrate to the inflamed tissue, promote
recruitment of inflammatory monocytes and potentiate the pro-
inflammatory environment allowing to appropriately deal with
the inflammogen (Mantovani et al, 2011). Under normal
conditions, neutrophils undergo apoptosis after performing
their action at the inflamed site (Fox et al, 2010) and
macrophages ingest apoptotic neutrophils. Clearance of apo-
ptotic neutrophils prompts a switch from a pro- to an anti-
inflammatory macrophage phenotype (Fadok et al, 1998;
Michlewska et al, 2009), which is a prerequisite for macrophage
egress via the lymphatic vessels favouring return to tissue
homeostasis (Fig 1).
The past few years have witnessed an appreciation of the
complex resolution of inflammation process, characterized by
molecular and cellular events that ultimately assure tissue repair
and regain of physiological function. A crucial point is the
concept that resolution is an active phenomenon, aimed at
actively suppressing and extinguishing a vibrant inflammatory
reaction once its main objective (e.g. clearance of bacteria) is
attained. In this review we highlight the essential mechanisms
underlying resolution of inflammation and discuss how these
mechanisms can be targeted to accelerate return to tissue
integrity.
Chemokine depletion sets the brakes on
neutrophil tissue infiltration
Chemokines are molecular cues that orchestrate leukocyte
migration to sites of inflammation. Abrogation of neutrophil
influx is a prerequisite for resolution of inflammation and
mechanisms such as chemokine cleavage by proteolysis and
chemokine sequestration are necessary to attain a resolving
environment (Fig 2A). Macrophage-specific MMP12 cleaves
CXC chemokines in the ELR motif, which is crucial for receptor
binding, thus rendering them unable to recruit neutrophils
(Dean et al, 2008). MMP-dependent chemokine cleavage also
depletes CC-chemokines that preferentially attract classical
monocytes. For instance, cleaved CCL7 continues to bind CCR1,
CCR2 and CCR3, but fails to induce downstream signalling and
chemotaxis, thus acting as a general antagonist dampening
inflammation (McQuibban et al, 2000, 2002).
Chemokine receptors possess a conserved DRY motif in
the second intracellular loop which is involved in coupling
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to G-proteins. Receptors lacking the DRY motif sequester
chemokines without launching a signalling cascade and are
hence termed decoy receptors (Mantovani et al, 2006).
Prominent members of this subfamily are duffy antigen receptor
for chemokines (DARC) and D6. DARC is predominantly
expressed by endothelial cells near sites of leukocyte extra-
vasation and can sequester CC and CXC pro-inflammatory
chemokines (Gardner et al, 2004). The lack of this atypical
chemokine receptor leads to increased neutrophil influx
into lung and liver upon application of lipopolysaccharide
(LPS; Dawson et al, 2000; Luo et al, 2000) hence supporting
its importance in termination of neutrophil recruitment. D6
on the other hand, binds a broad range of CC chemokines
including most agonists of CCR1, CCR2 and CCR5 (Bonecchi
et al, 2004). D6-deficient mice exhibit a dysregulated inflam-
matory reaction with impaired clearance of chemokines,
resulting in tissue accumulation of neutrophils (Jamieson
et al, 2005). After myocardial infarction, D6 prevents excessive
infiltration of classical monocytes and neutrophils by scavenging
CCL2 (Cochain et al, 2012) a phenomenon functionally associated
with adverse remodelling and reduced ejection fraction. Another
atypical chemokine receptor, CCX-CKR, scavenges constitutive
chemokines such as CCL19, CCL21 and CCL25 which control
homeostatic leukocyte trafficking. Therefore, an overriding
function of this receptor in the resolution of inflammation
appears rather unlikely (Bunting et al, 2013).
A sophisticated mechanism for chemokine entrapment is
the generation of functional decoy receptors from classical
chemokine receptors. In an environment rich in microbial
peptides or pro-inflammatory cytokines, IL10 inhibits down-
regulation of CCR1, CCR2 and CCR5, but these receptors are
now unable to translate ligand binding into cell migration, thus
trapping pro-inflammatory chemokines (D’Amico et al, 2000). A
similar mechanism is centred on the up-regulation of CCR5 on
apoptotic neutrophils leading to depletion of pro-inflammatory
chemokines during the resolution phase of acute murine
peritonitis (Ariel et al, 2006).
Neutrophil apoptosis is central to resolution
Aborted neutrophil recruitment is but one of the steps required
to reconstitute tissue homeostasis, clearance of neutrophils
must also be achieved in due time. Despite the recent
controversy regarding the life span of neutrophils (Dixon
et al, 2012; Pillay et al, 2010), they are in general considered to
be short-lived. Once emigrated, the lifespan of neutrophils can
be modified by the local inflammatory environment (Fox et al,
2010; Geering & Simon, 2011; Fig 2B). For instance, macro-
phages secrete death receptor ligands such as Fas-ligand and
TNF to promote neutrophil survival at low concentrations and
neutrophil death at higher concentrations (van den Berg et al,
2001). In this regulatory pathway, phosphoinositide 3-kinase
(PI3K)-mediated reactive oxygen species (ROS) production
represents the key event in limiting cell survival and triggering
apoptosis (Geering et al, 2011). Furthermore, Btk, a negative
regulator of NADPH activation, is associated with neutrophil
survival. Thus, Btk-deficient neutrophils feature high levels
of ROS production, driven by excessive NADPH and PI3K
activation (Honda et al, 2012). Other environmental signals
such as hypoxia extend neutrophil lifespan; neutrophilic
inflammation occurs in hypoxic environments, where
hypoxia-inducible factor-1a (HIF1a) interferes with neutrophil
survival (Walmsley et al, 2011). Finally, GM-CSF, a survival
factor for neutrophils, triggers ERK activation and interference
with ERK or other life span prolonging signalling pathways may
allow for induction of neutrophil apoptosis.
Intriguingly, apoptotic neutrophils may attenuate inflamma-
tion through distinct mechanisms. Dying neutrophils secrete
mediators that inhibit further neutrophil recruitment. One is
annexin A1 (AnxA1; 37 kDa), a protein abundant in the
cytosol of resting neutrophils. AnxA1 translocates to the
plasma membrane when activated, where it interacts with
the formyl peptide receptor 2 (FPR2/ALX) to moderate leukocyte
adhesion and migration (Dalli et al, 2008; Perretti et al, 2002).
It also promotes neutrophil apoptosis and clearance of dead
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Glossary
Annexin A1
A glucocorticoid-regulated protein, highly abundant in myeloid cells such
as neutrophils and macrophages, with profound effects on several phases
of the resolution of inflammation.
Chemokines
Low molecular weight cytokines with chemotactic effects on leukocytes.
Decoy receptor
Receptor for cytokines that, while irreversibly binding to its ligands, does
not trigger activation of the corresponding intracellular signalling
pathway, hence acting as a scavenger of these molecules.
Efferocytosis
Phagocytosis and clearance of an apoptotic cell.
Find me/eat me signals
Group of molecules secreted or exposed at the surface of an apoptotic cell
that guide efferocytes to facilitate their disposal.
Liposome
Spherical particle composed by a lipid bilayer, containing a lumen with the
capacity to encapsulate and transport substances in biological systems,
thus being a suitable vehicle for drug delivery.
Myeloid derived suppressor cells
Heterogeneous population of early myeloid progenitors with the ability to
suppress T cells activity.
Pro-resolving lipid mediators
Bioactive lipids secreted in response to an inflammatory state that
stimulate molecular and cellular events to achieve resolution.
Resolution-phase macrophage
Macrophage that, in response to stimuli announcing the conclusion of an
acute inflammation, reprograms its phenotype and acts towards the
termination of the inflammatory process and return to homeostasis.
TReg
Naturally immunosuppressive subpopulation of CD4þ T cells characterized
by constitutive expression of the transcription factor Foxp3.
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neutrophils by macrophages (Perretti & Solito, 2004; Scannell
et al, 2007). Another neutrophil-derived protein with similar
activities is lactoferrin. It is contained within the secondary
granules of neutrophils and when released, lactoferrin binds to
specific receptors that trigger MAPK-mediated intracellular
signalling, which is crucial in the regulation of cytoskeletal
remodelling and cell adhesion (Bournazou et al, 2009). In a
model of acute lung injury, lactoferrin application prevents
neutrophil tissue infiltration, oedema formation and improves
lung function (Table 1; Li et al, 2012). Nonetheless, lactoferrin
exerts survival effects on neutrophils in rheumatoid arthritis
(Wong et al, 2009) depending on its iron saturation level
(Francis et al, 2011). Thus, the survival/apoptosis balance in
neutrophils is monitored by an intricate and complex network
of signalling factors which might present opposite effects
depending on their concentration (e.g. TNF) or iron saturation
state (e.g. lactoferrin).
Apoptotic neutrophils are cleared by macrophages via
efferocytosis. Apoptotic neutrophils promote their own clear-
ance by expressing find me and eat me signals (Fig 2C). Find me
signals are secreted factors that attract scavengers. To date, four
major find me signals have been described: lysophosphatidyl-
choline (LPC), sphingosine 1-phosphate (S1P), fractalkine
(CX3CL1), and the nucleotides ATP and UTP (Elliott et al,
www.embomolmed.org Review
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Figure 1. Cellular interplay during resolution of inflammation. Overview of cellular processes during onset (left) and resolution (right) of inflammation. During
early phases of inflammation tissue-resident cells sense damage and launch the release of signals that induce rapid neutrophil and delayed monocyte emigration.
Resolution is initiated when neutrophils become apoptotic thus secreting mediators that inhibit continued neutrophil infiltration. Ingestion of apoptotic
neutrophils changes the macrophage phenotype towards a resolution-phase macrophage, which promotes return to tissue homeostasis. A switch in tissue
(stromal) cells can also contribute to generate the initial signals for resolution to start.
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2009; Gude et al, 2008; Lauber et al, 2003; Truman et al, 2008).
Find me signal gradients guide the efferocyte towards the dead
cell through the involvement of G2A, S1P1-5, CX3CR1, and P2Y2
receptors, respectively. Eat me signals are surface markers
which allow the identification of a dying cell. These signals can
be either molecules exposed de novo at the cell membrane or
existing ones that undergo modifications during apoptosis, as
for instance peptides derived from the AnxA1 N-terminal
domain (Blume et al, 2012). Phosphatidylserine (PS) on the
outer membrane of the apoptotic cell is the best-known eat me
signal. Direct recognition of PS by the efferocyte is mediated by a
variety of receptors including TIM4, BAI1, stabilin-2 and the
receptor for advanced glycation end products (RAGE; He et al,
2011; Ravichandran, 2011). In contrast, other receptors are
engaged via soluble bridging molecules, one example being
AnxA1 that links PS to the PS receptor (Arur et al, 2003).
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Figure 2. Mechanisms of neutrophil- and macrophage-driven resolution.
A. Depletion of chemokines during resolution. MMPs cleave CC and CXC chemokines rendering them non-functional. Structural decoy receptors such as D6
and DARC sequester chemokines without subsequent signal transduction. Functional decoy receptors are classical chemokine receptors with repressed
signalling.
B. Factors controlling neutrophil life span at sites of inflammation. Interestingly, the pro-apoptotic stimuli can often override those that augment neutrophil life
span.
C. Upon apoptosis find me signals such as nucleotides, S1P, CX3CL1 and LPC are released that attract scavengers. These recognize apoptotic cells via eat me signals
exposed on the cell surface. Clearance is mediated by direct cell–cell contact or by involvement of bridging molecules.
D. In response to local mediators and upon efferocytosis, pro-inflammatory macrophages switch to resolution-phase macrophages.
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Table 1. In vivo approaches to induce resolution of inflammation
Disease model Drug Effect on resolution Refs.
Inhibition of leukocyte recruitment
Air pouch model in mice AnxA1 of human neutrophil-
derived microparticles
Decrease of leukocyte infiltration Dalli et al (2008)
Rheumatoid arthritis
in mice
LXA4 Decrease of oedema, neutrophil influx, and mRNA levels
of CXCL1, LTB4, and TNF after LXA4 treatment
Conte et al (2010)
Peritonitis in mice Nanoparticles containing
aspirin-triggered RvD1 or a
lipoxinA4 analogue
Reduced neutrophil influx into the peritoneum, and
resolution intervals
Norling et al (2011)
LPS-induced ALI lactoferrin Reduced lung neutrophil infiltration with less oedema
and plasma leakage
Li et al (2012)
Air pouch and skin
inflammation in mice
LXA4 analogue Reduced neutrophil infiltration Clish et al (1999)
Peritonitis in mice RvE1 Reduced leukocyte infiltration into the peritoneum Arita et al (2005)
Colitis in mice RvE1 Increased survival rates, sustained body weight, improve-
ment of histologic scores, reduced serum anti-2,4,6-trini-
trobenzene sulfonic acid IgG and reduction of leukocyte
infiltration and pro-inflammatory gene expression
Arita et al (2005)
Peritonitis in mice Chemerin C15 Reduction of neutrophil and monocyte infiltration into the
peritoneum, enhancement of apoptotic cell phagocytosis of
by macrophages and reduction of pro-inflammatory mediators
Cash et al (2008)
Induction of neutrophil apoptosis
Acute pleurisy, lung
injury and arthritis
in mice
R-roscovitine (CDK inhibitor) Reduced presence of inflammatory cells (neutrophil and
monocytes/macrophages) and amelioration of disease
according to clinical scores
Rossi et al (2006)
Acute lung injury mice 15-epi-LXA4 Increased neutrophil apoptosis and efferocytosis El Kebir et al (2009)
Lung inflammation
in rats
Ectoine Restoration of normal neutrophil apoptosis rates (Sydlik et al 2013)
Pleurisy in rats PD98059 (ERK inhibitor) Decrease of total number macrophages and neutrophils in
the pleural cavity, increased rate of neutrophil apoptosis
Sawatzky et al (2006)
Acute pleurisy in mice Ac2-26 (AnxA1-active N-terminal
peptide)
Reduction of neutrophils by induction of neutrophil
apoptosis
Vago et al (2012)
Peritonitis in mice Histone deacetylase inhibitors AnxA1-dependent decrease in neutrophil, monocyte and
macrophage infiltration
Montero-Melendez
et al (2013)
Enhancement of efferocytosis and macrophage reprogramming
Microbial peritonitis/air
pouch model in mice
RvD1, RvD5, PD1s Enhancement of bacterial killing, neutrophil efferocytosis
and prevention of hypothermia. Acceleration of resolution in
combination with antibiotics
Chiang et al (2012)
Allergic airway
inflammation model
in mice
RvE1 Suppression of the production of IL17, IL23 and IL6 and
increased concentration of IFN-g and LXA4 in
brocheoalveolar lavage fluid, decrease of resolution
intervals, acceleration of resolution of allergic airway
pathology and hyper-responsiveness
Haworth et al (2008)
Sepsis model in rats LXA4 Increase of animal survival, decrease of blood bacterial load
and pro-inflammatory mediators
Walker et al (2011)
Peritonitis in mice RGD-AnxA5 Enhancement of engulfment of apoptotic cells by macro-
phages and increase of secretion of IL10 during efferocytosis
Schutters et al (2013)
CGD in mice IFN-g Enhanced engulfment of apoptotic cells by macrophages Fernandez-Boyanapalli
et al (2010)
Peritonitis in CGD mice IFN-g Enhanced engulfment of apoptotic cells by macrophages Fernandez-Boyanapalli
et al (2010)
Early renal fibrosis
in rats
LXA4/benzoLXA4 Prevention of collagen deposition and renal apoptosis.
Inhibition of TNF production and stimulation of IL10
Borgeson et al (2011)
CGD in mice IL4 Normalized CGD macrophage efferocytosis Fernandez-Boyanapalli
et al (2009)
CGD in mice PS Restored IL4-dependent macrophage reprogramming
and efferocytosis
Fernandez-Boyanapalli
et al (2009)
Stimulation of tissue repair
Mucosal injury and
ulceration in mice
AnxA1 Promotion of intestinal epithelial migration trough
activation of FPR1-, Rac1- and NOX1-dependent redox
signalling to induce wound repair
Leoni et al (2013)
Rheumatoid arthritis
model in mice
Flavopiridol (CDK inhibitor) Suppression of synovial hyperplasia and joint destruction Sekine et al (2008)
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Similarly, MFG-E8 links PS and the vitronectin receptor, Gas 6 or
Protein S facilitate contact between PS and TAM receptors, and
b2-glycoprotein-I with its receptor and PS (Stitt et al, 1995).
How these various receptors signal intracellularly to mediate
cytoskeletal rearrangement thereby facilitating corpse uptake
remains to be understood.
A functional macrophage switch governs the
return to tissue homeostasis
Macrophages possess a striking functional and phenotypic
plasticity that becomes apparent during the resolution phase of
inflammation. Upon apoptotic cell efferocytosis, macrophages
turn off production of pro-inflammatory cytokines and lipid
mediators and launch an anti-inflammatory transcriptional
program characterized by the release of IL10 and TGF-b (Fadok
et al, 1998; Fig 2D), quite reminiscent of the M2 alternative
macrophage activation pattern. Transcriptomic analyses of
murine resolution-phase macrophages shed light on the main
features of macrophages during resolution in vivo (Stables et al,
2011). Resolution-phase macrophages are rich in molecules
important for antigen processing and presentation and secrete
T- and B-cell chemoattractants (XCL1, CCL5 and CXCL13).
Consequently, the lymphocytes that repopulate sites of resol-
ving inflammation comprise B1, NK, gdT, CD4þCD25þ and B2
cells which might exert a protective effect in the post-resolution
phase (Rajakariar et al, 2008). In addition, resolution-phase
macrophages express TIM4 and TGF-b, key molecules in
the clearance of inflammatory cells and the return to tissue
homeostasis. Functional characterization of resolving macro-
phages revealed lower levels of CD11b, enhanced capacity to
engulf dead neutrophils, reduced responsiveness to TLR4
ligands, thus possibly leading to a ‘‘satiated’’ state with the
ultimate departure through the lymph (Schif-Zuck et al, 2011).
Clearly, the latter two studies indicate heterogeneity of
resolution-phase macrophages and call for a standardization
of the classification criteria. A chemokine scavenging-indepen-
dent role for D6 in promoting macrophage-mediated resolution
has recently been outlined. D6-deficient macrophages display
a defect in conversion to a resolution phase macrophage.
Furthermore, senescent human neutrophils and resolution-
phase murine neutrophils present an increased expression of
D6, suggesting that D6 might play a role in the interactions of
apoptotic neutrophils with macrophages, as well as satiation of
these macrophages (Pashover-Schallinger et al, 2012).
In addition, rapidly generated lipid mediators play a key
role in orchestration of inflammation and its resolution
(Serhan et al, 2008). In particular, the arachidonic acid pathway
synthesizes pro-inflammatory lipids such as prostaglandin
(PG) E2 and D2, and, during the resolution phase, pro-resolving
bioactive lipid mediators including lipoxins and the
v3-unsaturated fatty acid-derivatives termed resolvins and
protectins. Intriguingly, differential gene regulation of arachi-
donate metabolism-related enzymes has been reported in
M1- and M2-polarized human macrophages (Martinez et al,
2006). M1 macrophages display a marked induction of COX2,
with down-regulation of COX1, leukotriene A4 hydrolase,
thromboxane A synthase 1 and arachidonate 5-lipoxygenase.
Conversely, M2 macrophages show up-regulation of arachido-
nate 15-lipoxygenase and COX1. Furthermore, microsomal PGE
synthase, the key enzyme in PGE2 production, is induced in
macrophages by inflammatory M1 signals such as LPS and is
functionally coupled to COX2 expression. In contrast, M2
stimuli such as IL4 and IL13 down-regulate mPGES expression
in macrophages.
Functionally, lipoxin A4 (LXA4) inhibits neutrophil entry to
tissue sites while promoting monocyte migration (Maddox et al,
1997). Cell-type specific signalling pathways downstream of
FPR2/ALX activation by LXA4 can explain this differential effect
(Chiang et al, 2006). Changes in cytoskeletal protein phosphor-
ylation with consequent cell arrest occur in neutrophils exposed
to LXA4, whilst mobilization of intracellular Ca2þ occurs in
monocytes and macrophages, thus promoting chemotaxis.
LXA4, at low nanomolar concentrations, generally decreases
neutrophil activity, with lower levels of CD11b/CD18 expres-
sion, ROS formation and NFkB activity, as well as decreased
synthesis of pro-inflammatory chemokines and cytokines. In
monocytes and macrophages, LXA4 also promotes non-
phlogistic phagocytosis of apoptotic neutrophils with reduced
release of CXCL8 (Jozsef et al, 2002). Resolvins are another class
of pro-resolving lipid mediators that were initially identified in
exudates from mouse air-pouch models during the spontaneous
resolution of inflammation. Resolvin E1 binds ChemR23 on
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Disease model Drug Effect on resolution Refs.
Rheumatoid arthritis
model in mice
CDK4/6-selective inhibitor Suppression of synovial hyperplasia and joint destruction Sekine et al (2008)
Peritoneal and lung
inflammation in mice
PS/PC liposomes Induction of TGF-b secretion, resulting in accelerated
resolution of inflammation
Huynh et al (2002)
Myocardial infarction in rats PS/PC liposomes Induction of angiogenesis, preservation of small scars,
prevention of ventricular dilatation and remodelling
Harel-Adar et al (2011)
Retinal ischaemia in mice PS/PC liposomes Reduced expression of pro-inflammatory genes, reduced
neuronal death in the retina after ischaemia-reperfusion
Dvoriantchikova
et al (2009)
Liver cirrhosis in rats Vitamin A-coupled liposomes
carrying siRNAgp46
Decrease in collagen recreation from HS cells and abroga-
tion of hepatic stellate cells in fibrotic tissue through
apoptosis, resulting in reduced fibrotic area in rat kidneys
Sato et al (2008)
ALI, acute lung injury; Anx, annexin; CGD, chronic glomerular disease; LXA4, IFN, interferon; Lipoxin A4; PC, phosphatidylcholine; PS, phosphatidlyserine; Rv,
resolving.
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monocytes, macrophages and dendritic cells to attenuate
TNF-mediated NFkB activation, thus forming an anti-
inflammatory signalling pathway (Arita et al, 2007). Further-
more, resolvin E1 reduces neutrophil infiltration in murine
peritonitis and shortens the resolution interval while modifying
the expression of miRNAs that target genes involved in
resolution (Recchiuti et al, 2011). This effect appears to involve
specific G protein-coupled receptors, namely ALX/FPR2 and
GPR32 (Krishnamoorthy et al, 2012).
Restoration of tissue functionality
The functional recovery of homeostasis after an inflammatory
injury requires tissue repair and reestablishment of tissue
functionality. The underlying mechanisms are complex and
tissue-dependent but require a tight interplay between macro-
phages, stem and progenitor cells, together with stromal cells
to prevent fibrosis or scar formation, a pathophysiological
condition that leads to ineffective and inappropriate tissue
function. Landmark studies have shown that macrophages
orchestrate these reparative processes (Leibovich & Ross, 1975;
Polverini et al, 1977). Recent work points towards a critical role
of alternatively activated macrophages (Lucas et al, 2010;
Saclier et al, 2013; Sindrilaru et al, 2011), which secrete anti-
inflammatory and reparative mediators including IL1 receptor
antagonist, IL10, TGF-b and VEGF. The generation of growth
factors promotes cell proliferation and protein synthesis in
neighbouring cells (Rappolee et al, 1988), while the production
of proteases and their inhibitors regulate extracellular matrix
(ECM) composition and remodelling. Macrophage-derived
TGF-b contributes to tissue regeneration and wound repair by
promoting (i) fibroblast differentiation into myofibroblasts,
(ii) expression of tissue inhibitors of metalloproteinases (TIMPs)
that regulate ECM remodelling and (iii) synthesis of interstitial
fibrillar collagens by myofibroblasts. Macrophages also produce
the majority of wound-associated VEGF, assuring angiogenesis
and restoration of oxygen supply (Knighton et al, 1983). M2
macrophages also produce MMPs and TIMPs that control ECM
turnover engulf and digest various ECM components that would
promote tissue-damaging M1 macrophage responses (Atabai
et al, 2009), and secrete specific chemokines that recruit
fibroblasts and regulatory T (TReg) cells (Curiel et al, 2004).
There is scattered evidence supporting the hypothesis that
macrophages interact with progenitor or stem cells, and that this
interplay may contribute to repair and remodelling. Mesen-
chymal stem cells (MSCs) are candidates for cellular therapies
aimed at promoting tissue repair or immunoregulation (Uccelli
et al, 2008). MSCs engage in a bidirectional interaction with cells
of the macrophage lineage. M2-like macrophages and their
mediators promote growth of human MSCs (Freytes et al, 2013)
and can also stimulate MSC motility (Anton et al, 2012).
Conversely, MSCs profoundly influence macrophage function
by inducing a IL10high IL12low alternative activation phenotype
(Kim & Hematti, 2009). Injection of MSCs is associated with
promotion of functional recovery after spinal cord injury,
including axonal preservation and reduced scar formation
(Nakajima et al, 2012). Neuroprotection in this system is
attributed to MSC-induced shift in macrophage polarization
from M1 to M2.
The fate of infiltrating macrophages is not fully understood. It
has been postulated that after performing their central tasks in
resolution, macrophages emigrate to the draining lymph node,
where they may play an important role in the presentation of
antigens from the inflamed site (Bellingan et al, 1996). MMP-
mediated shedding of b2 integrin seems important for macro-
phage egress from the injured tissue (Cao et al, 2005; Gomez
et al, 2012). A failure in macrophage egression results in
accumulation and may potentially lead to chronic inflammatory
diseases, such as atherosclerosis (Llodra et al, 2004).
Suppressive immune cells as emerging players in
resolution
Although neutrophils and macrophages have traditionally been
looked upon as dominant cell types during the resolution phase,
accessory cells such as myeloid-derived suppressor cells
(MDSCs) and TReg have more recently emerged as important
players during resolution and may link innate and adaptive
immune systems (Fig 3).
TReg, a subset of CD4
þCD25þ T lymphocytes that co-express the
transcription factor Foxp3 (Hori et al, 2003), regulate immune
responses through the secretion of immunosuppressive and pro-
resolving cytokines such as IL10 and TGF-b, thus being key
players in immunehomeostasis (Asseman et al, 1999; Fahlen et al,
2005). To date, beneficial roles of TReg have emerged in a number
of inflammatory diseases including rheumatoid arthritis (Cao et al,
2003), multiple sclerosis (Viglietta et al, 2004) and atherosclerosis
(Ait-Oufella et al, 2006). Traditionally, TReg are activated in an
antigen-dependent manner to inhibit self-reactive or pathogenic
T cells. However, TReg may also exert functions independent of
inhibition of lymphocyte function, as was shown in a model of
LPS-induced acute lung injury (D’Alessio et al, 2009). The transfer
of wild type TReg to Rag1
/ mice lacking mature T and B cells
caused abrogation of lung inflammation, accompanied by
increased apoptosis of alveolar neutrophils and macrophage
efferocytosis, together with reduced pro-inflammatory cytokines
and doubling of TGF-b levels. TReg abrogated TNF production and
boosted TGF-b release in isolated alveolar macrophages in a
contact-dependent manner. These results are in line with a
previous study demonstrating that anti-inflammatory macro-
phages induce differentiation of TReg via TGF-b (Savage et al,
2008). These findings highlight the cross-talk between innate and
adaptive immunity where cells of both systems regulate each
other to coordinate resolution.
MDSCs represent a heterogenic population of immature
myeloid cells expressing Gr1 and CD11b in mice and suppress
T-cell functions (Bronte et al, 2000; Ribechini et al, 2010). In
healthy individuals immature myeloid cells migrate to different
peripheral organs, where they differentiate into dendritic cells,
macrophages and/or granulocytes. However, under pathologi-
cal conditions such as acute or chronic infection, sepsis, trauma
or tumours, their differentiation is partially blocked leading to
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the generation and accumulation of MDSC. One of the original
features of MDSCs is the production of arginase I (ARG1) or
inducible nitric oxidase synthase (iNOS) that initiate the release
of nitric oxide (NO) and ROS involved in programmed cell death
or apoptosis and other immunosuppressive mechanisms (Gab-
rilovich & Nagaraj, 2009). The transcription factor STAT1 is of
key importance in the signalling pathway leading to increased
expression of ARG1 and iNOS. Indeed, MDSCs from Stat1/
mice fail to up-regulate these enzymes and therefore do not
inhibit T-cell responses (Kusmartsev et al, 2005). In contrast to
MDSCs, neutrophils create a pro-inflammatory environment
upon activation that further activates T cells and can induce their
differentiation by release of IL12, IL4 or IL6 (Muller et al, 2009).
MDSCs exert beneficial activities in inflammatory conditions
such as sepsis, inflammatory bowel disease, autoimmune
encephalomyelitis and multiple sclerosis (Delano et al, 2007;
Haile et al, 2008; Zhu et al, 2007). MDSCs also phagocytose
apoptotic neutrophils and produce large amounts of IL10
contributing to resolution in bacterial pneumonia (Poe et al,
2013). Interestingly, MDSCs induce expansion of TReg by
increasing their Foxp3 expression in a IL10, TGF-b and
arginase dependent manner (Huang et al, 2006; Serafini et al,
2008). Although research on the function of MDSCs in
resolution is still in its infancy, the latter findings suggest
that MDSCs might exert a regulatory role in resolution by
establishing a link with the adaptive immune system.
Therapeutic stimulation of resolution
Agents that target pro-inflammation mediators have dominated
drug research for inflammatory diseases for the last decades.
Current anti-inflammatory therapies control cardinal signs of
inflammation, mostly antagonizing specific pathways that are
engaged when acute inflammation sets in. To transfer of
concepts of resolution from bench to bedside requires a shift in
emphasis from inhibitory therapy to replacement therapy, i.e.
from antagonism to agonism. The advantage of immunoresol-
vents would be to limit continued neutrophil infiltration,
counter-regulate pro-inflammatory mediators, enhance the
containment and phagocytosis of cellular debris and apoptotic
neutrophils, and promote restoration of tissue homeostasis (Box
1). Therapies that actively promote resolution may also have the
advantage of enhancing innate immune responses to bacterial
infections (Chiang et al, 2012), whereas established anti-
inflammatory therapies such as anti-TNF strategies may be
immunosuppressive (Bruns et al, 2009).
Inhibition of leukocyte recruitment
The inhibition of continued leukocyte recruitment is essential to
favour the return to homeostasis. However, the therapeutic
targeting of cell adhesion molecules or chemokines to limit
inflammatory cell recruitment has so far been largely unsuc-
cessful. Pro-resolving AnxA1 dampens neutrophil tissue
accumulation by several mechanisms including downregulation
of transendothelial migration (Perretti et al, 1996), promotion of
neutrophil apoptosis (Perretti & Solito, 2004), and stimulation of
the removal of dead neutrophils (Scannell et al, 2007). The
combination of these mechanisms results in potent pro-
resolving effects in in vivo models of inflammation (Table 1;
Dalli et al, 2008; Vago et al, 2012). Similar activities have also
been ascribed to chemerin-derived peptides. While chemerin
primarily attracts antigen-presenting cells, C-terminal peptides
released from chemerin by cysteine proteases have opposite
effects—they block neutrophil tissue infiltration and the release
of pro-inflammatory mediators from classically activated
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Figure 3. Role of accessory cells in resolution. MDSCs clear apoptotic neutrophils, release anti-inflammatory IL10 and contribute to the expansion of TReg.
TReg stimulate neutrophil apoptosis, enhance the efferocytosis capacity of macrophages and secrete resolving cytokines like IL10 and TGF-b in a contact-
dependent manner.
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macrophages (Cash et al, 2008). In addition, chemerin-derived
peptides promote clearance of dead neutrophils bymacrophages
(Cash et al, 2010). Among the resolution-inducing agents,
resolving lipid mediators like LXA4, resolvin E1 and D1, and
protectins exert multiple pro-resolving effects, including
inhibition of neutrophil tissue infiltration, induction of neu-
trophil apoptosis and efferocytosis and stimulation of tissue
repair (Serhan et al, 2011). In animal models of inflammation,
resolvin E1 is protective in a model of colitis as shown by
decreased neutrophil tissue infiltration, pro-inflammatory gene
expression and improved survival (Arita et al, 2005). Similarly,
resolvin E1 reduces leukocyte infiltration in a mouse model of
asthma and ultimately improves lung function (Haworth et al,
2008). Although LXA4 is equally potent in inducing resolution,
due to rapid degradation in the blood stream, various delivery
strategies have evolved, including the use of stable forms such
as fluorinated analogues (Clish et al, 1999). Nanoparticles—
efficient delivery microstructures—can be enriched with
aspirin-triggered resolvin D1 or a LXA4 analogue to accelerate
resolution in experimental peritonitis (Norling et al, 2011).
Induction of neutrophil apoptosis
Given the central role of neutrophil apoptosis in resolution,
strategies aiming at the promotion of neutrophil apoptosis have
emerged (Table 1; Geering & Simon, 2011). Despite being end-
differentiated cells, the use of cyclin dependent kinase inhibitors
such as R-roscovitine has been demonstrated to promote
neutrophil apoptosis, leading to resolution in a wide range of
inflammatory models (Gherardi et al, 2004; Rossi et al, 2006;
Sekine et al, 2008; Zoja et al, 2007). However, a long-term
treatment that induces neutrophil apoptosis may attenuate the
innate immune response; hence molecules targeting the
inflammation-induced prolongation of neutrophil life span are
preferable. 5-epi-LXA4 induces resolution in a mouse model of
lung injury by counteracting the myeloperoxidase-mediated
suppression of neutrophil apoptosis (El Kebir et al, 2009).
Ectoine, a compatible solute with anti-inflammatory properties,
is able to prevent the anti-apoptotic mechanisms that extend
neutrophil life span in an inflammatory microenvironment.
Importantly, ectoine does not affect apoptosis of non-activated
neutrophils (Sydlik et al, 2013). Finally, PD098059, an ERK
inhibitor, was shown to counteract GM-CSF-induced neutrophil
survival and to promote resolution in a rat model of
carrageenan-induced pleurisy (Sawatzky et al, 2006).
Enhancement of efferocytosis and macrophage
reprogramming
An increase of neutrophil apoptosis without a ‘‘disposal
strategy’’ (i.e. efferocytosis) for the cell remnants perpetuates
inflammation. AnxA1, resolvins and LXA4 were all shown to
induce efferocytosis, which partially explains their resolution-
inducing activities in vivo (Table 1). In addition, in a model of
chronic granulomatous disease, IL4 administration induces
alternativemacrophage activationwith enhanced ability to clear
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BOX 1: Criteria for resolution-inducing mediators
Resolution, the return to normal inflammatory conditions, does not merely consist in catabolism of inflammatory mediators and
abrogation of inflammatory processes. Instead, resolution is an active and coordinated anti-inflammatory, pro-resolving
programme aimed at restoration of tissue homeostasis, integrity and function. Pro-resolving mediators should ideally fulfill the
following criteria:
1. Stop of inflammatory cell recruitment—the abrogation of neutrophil influx to block delivery of tissue-toxic proteases and
oxygen radicals is of crucial importance in resolution.
2. Induction of neutrophil apoptosis and clearance (efferocytosis)—removal of apoptotic neutrophils is of dual importance: it
induces reprogramming of macrophages and prevents spilling of potentially toxic contents from the neutrophil cytoplasm as they
become necrotic.
3. Egress of immune cells—following efferocytosis, macrophages and dendritic cells leave the site of inflammation.
4. Positive modulation of the immune response—instruction of suppressive immune cells and the adaptive immune response to
help dealing with subsequent encounters.
5. Induction of tissue repair—return to homeostasis without fibrosis or scar formation marks the final step of resolution.
#Recruitment "Apoptosis/
efferocytosis
"Egress "Immune
response
"Tissue
repair
Refs.
Annexin A1 þ þ N.D. þ þ Perretti & D’Acquisto (2009)
Chemerin C15 þ þ N.D. N.D. N.D. Cash et al (2008), Cash et al (2010)
Lipoxins þ þ þ þ þ Serhan et al (2008)
Resolvins þ þ þ No effect þ Ariel & Serhan (2007)
Galectin-1 þ N.D. N.D.  þ Ilarregui et al (2009)
Glucocorticoids þ þ N.D.   Perretti & D’Acquisto (2009)
Adenosine þ þ N.D. N.D. þ Csoka et al (2012), Koroskenyi et al (2011)
Melanocortins þ þ N.D. N.D. þ Patel et al (2011)
þ, stimulation; , inhibition; N.D., not defined.
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apoptotic neutrophils (Fernandez-Boyanapalli et al, 2009). A
recent study used an alternative strategy to enhance the surface
expression of eat me signals on apoptotic cells and ensure
clearance; delivery of AnxA5-RGD complexes that bind to PS on
apoptotic cells and on the vitronectin receptor on the efferocyte
would promote cell clearance and secretion of IL10 (Schutters
et al, 2013). Beyond their use as vehicles to deliver resolving
compounds (Metselaar et al, 2004), liposomes may also be used
to mimic apoptotic cells to induce macrophage reprogramming.
For instance, PS-containing liposomes can mimic the phagocyte
stimulation achieved by apoptotic cells and induce secretion of
pro-resolution mediators (Table 1). In addition, PS-liposomes
are preferentially ingested by macrophages (Geelen et al, 2012),
highlighting their potential in targeting macrophage-driven
resolution mechanisms.
Clinical trials of pro-resolving drugs
In addition to the pharmacological activities demonstrated in
animal models, several on-going clinical trials are yielding
positive results. Resolvin E1 (RX-10001) and a synthetic
analogue (RX-100045) are being tested in numerous inflamma-
tory diseases including dry eye, retinal disease, asthma,
inflammatory bowel diseases, rheumatic arthritis and cardio-
vascular diseases. RX-100045 has successfully completed the
phase II study in dry eye patients and is scheduled to enter a
phase III randomized, placebo-controlled, multi-centre study
(Lee, 2012). In another clinical study, a LXA4-based compound
was tested for the topical treatment of eczema (Wu et al, 2013).
Albeit in a small number of patients, the drug reduced the
severity of eczema to a similar extent as steroid therapy in a
double-blind placebo-controlled setting, thus indicating efficacy
and safety of resolving mediators in a clinical study. AP214, a
melanocortin agonist developed by Action Pharma AS (recently
acquired by Abbott), elicits pro-resolving and tissue-protective
effects in experimental systems (Montero-Melendez et al, 2011);
in clinical settings, it effectively reduces acute kidney injury
associated with major cardiac surgery. This study offers positive
expectations as it has presented phase 2b top-line results in the
evaluation of the efficacy, safety and tolerability of the
compound. A second phase 2b study is scheduled for the end
of 2012.
Conclusion
Our understanding of resolution as an active process has come a
long way since the early observations by Elie Metchnikoff who
observed that neutrophils are phagocytosed by macrophages
and how this clearance resolves tissue inflammation (Mechni-
kov, 1988). Resolution is now looked upon as a complex process
where apoptosis of neutrophils and their subsequent clearance
herald potent anti-inflammatory, tissue-restoring mechanisms.
To fully appreciate the complexity of such processes and to
design resolution-based therapeutic strategies, future work is
needed to discern differences in the mechanisms of resolution in
acute and chronic inflammatory disorders as well as decipher
the tissue-specific resolution networks.
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